{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:40:18Z","timestamp":1793252418152,"version":"4.5.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Encapsulation of mRNA in lipid nanoparticles (LNPs) has established the LNP\u2013mRNA platform as the strategy of choice for the rapid development of vaccines against both existing and emerging pathogens. However, despite its widespread global implementation during the COVID-19 pandemic, the immunological mechanisms underlying its efficacy remain incompletely understood. In this study, we investigated in a murine model, the early and robust innate immunity events elicited following immunization with an LNP\u2013mRNA vaccine. Using mRNAs encoding two different proteins as well as a non-coding sequence, it is demonstrated that the mRNA component\u2014rather than the LNP or the encoded antigen \u2014is essential for inducing a potent innate immune response. This response is characterized by rapid activation of dendritic cells, recruitment of monocytes to draining lymph nodes, and systemic cytokine responses involving activation of various innate immune cell populations. Notably, these effects are all dependent on signaling through the type I interferon receptor (IFNAR). Importantly, we show that even a brief and transient inhibition of IFNAR signaling significantly enhances the ability of the LNP\u2013mRNA vaccine to elicit adaptive immune responses, as evidenced by increased frequencies of antigen-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and elevated titers of antigen-specific antibodies. Together, our findings reveal that the strong IFNAR-dependent innate response induced by mRNA can attenuate subsequent adaptive immunity. These insights should be considered in the future design and optimization of LNP\u2013mRNA vaccine platforms.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1670350","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:41:46Z","timestamp":1760506906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["The mRNA component of LNP-mRNA vaccines triggers IFNAR-dependent immune activation which attenuates the adaptive immune response"],"prefix":"10.3389","volume":"16","author":[{"given":"Liat","family":"Bar-On","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilach","family":"Cherry-Mimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Erez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"Payne","year":"2021","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/82_2020_202","article-title":"Messenger RNA-based vaccines against infectious diseases","volume":"440","author":"Alameh","year":"2022","journal-title":"Curr Top Microbiol Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr Opin Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles horizontal line From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.05.005","article-title":"Modulation of adaptive immunity with Toll-like receptors","volume":"21","author":"Manicassamy","year":"2009","journal-title":"Semin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010061","article-title":"Immune responses induced by mRNA vaccination in mice, monkeys and humans","volume":"9","author":"Cagigi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"109504","DOI":"10.1016\/j.celrep.2021.109504","article-title":"Systemic IL-15, IFN-gamma, and IP-10\/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients","volume":"36","author":"Bergamaschi","year":"2021","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.03.015","article-title":"Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers","volume":"28","author":"Maruyama","year":"2022","journal-title":"J Infect Chemother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0378-3","article-title":"Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging","volume":"3","author":"Lindsay","year":"2019","journal-title":"Nat BioMed Eng"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01168-4","article-title":"Making innate sense of mRNA vaccine adjuvanticity","volume":"23","author":"Kobiyama","year":"2022","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s42003-023-04555-1","article-title":"Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals","volume":"6","author":"Connors","year":"2023","journal-title":"Commun Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"34215","DOI":"10.1038\/srep34215","article-title":"A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates","volume":"6","author":"Swaminathan","year":"2016","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1038\/s41467-024-51411-9","article-title":"Innate immune responses against mRNA vaccine promote cellular immunity through IFN-beta at the injection site","volume":"15","author":"Kim","year":"2024","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.1c01284","article-title":"Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection","volume":"21","author":"Elia","year":"2021","journal-title":"Nano Lett"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg1036","article-title":"A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium","volume":"9","author":"Kon","year":"2023","journal-title":"Sci Adv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Baiersdorfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.100922","article-title":"Early and delayed STAT1-dependent responses drive local trained immunity of macrophages in the spleen","volume":"13","author":"Solomon","year":"2025","journal-title":"Elife"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3946320241260262","DOI":"10.1177\/03946320241260262","article-title":"Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice","volume":"38","author":"Xu","year":"2024","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.08.012","article-title":"Innate recognition of viruses","volume":"27","author":"Pichlmair","year":"2007","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.04.025","article-title":"A triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors","author":"Wang","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.6.3315","article-title":"Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection","volume":"176","author":"Havenar-Daughton","year":"2006","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.8.4682","article-title":"Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming","volume":"176","author":"Le Bon","year":"2006","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241148","article-title":"Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection","volume":"222","author":"Broomfield","year":"2025","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"102035","DOI":"10.1016\/j.xcrm.2025.102035","article-title":"Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity","volume":"6","author":"Tursi","year":"2025","journal-title":"Cell Rep Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110654","article-title":"Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo","volume":"208","author":"Swiecki","year":"2011","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.175401","article-title":"Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans","volume":"9","author":"Hellgren","year":"2024","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"B47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-kappaB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.161","article-title":"Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses","volume":"24","author":"De Beuckelaer","year":"2016","journal-title":"Mol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.01.006","article-title":"Type I interferons modulate CD8(+) T cell immunity to mRNA vaccines","volume":"23","author":"De Beuckelaer","year":"2017","journal-title":"Trends Mol Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.5.1655","article-title":"Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells","volume":"178","author":"Brinkmann","year":"1993","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238543","article-title":"Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists","volume":"115","author":"Rajagopal","year":"2010","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1670350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:41:47Z","timestamp":1760506907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1670350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2025.1670350"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1670350","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1670350"}}